Bio Path reported $297K in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Alterity Therapeutics Limited AUD 8.67M 893.38K Dec/2025
Baxter International USD 2.68B 3.36B Jun/2026
Bio Path USD 297K 191K Mar/2026
Cipla INR 62.31B 3.04B Jun/2026
Clal Biotechnology ILS 5.15M 9.47M Dec/2022
Compugen USD 11.19M 96K Mar/2026
CSL USD 5.7B 2.82B Dec/2025
Grifols EUR 1.99B 217.4M Dec/2025
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026